Hematology and oncology
DGHO Congress in Berlin: News from blood and cancer research
–
| Reading time: 2 minutes
–
The DGHO congress will take place in Berlin this year.
–
Photo: Schoening Berlin / picture alliance / Arco Images
This year’s DGHO congress takes place in Berlin. Experts will discuss on site in the CityCube. These issues are central.
–
–
Berlin. The annual meeting of the German Society for Hematology and Medical Oncology (DGHO) begins today in Berlin. As usual, the event will be held together with the Austrian and Swiss partners. This year the symposium will take place as a hybrid solution: on site in the “CityCube Berlin” and in the livestream. For four days, experts from various fields will present the latest findings on the diagnosis and treatment of blood diseases and cancer.
“This year, the congress stands for mutual exchange,” said Andreas Mackensen, congress president of the German Society for Hematology and Oncology. Last year, the symposium was only broadcast online due to the corona. “We have to get back to the conversation,” said the congress director in favor of the event on site.
The main focus this year is on the use of RNA vaccines for the treatment of tumors in cancer patients. Researcher Özlem Türeci (Biontech) will give a lecture on this Saturday. RNA vaccines have evolved from tumor vaccines to corona vaccines in order to contain the coronavirus. Research is now to be continued into how the vaccines can be used for immunotherapy against cancer. It is important to talk about how the coronavirus vaccines can be used in people with cancer. After all, the Standing Vaccination Commission (STIKO) recommends vaccinating cancer patients. “Vaccinating cancer patients does not represent an increased risk. However, it is not clear whether the vaccines will work in those affected by certain types of cancer,” explains Mackensen.
